Bristol-Myers Squibb Total Assets 2006-2018 | BMY

Bristol-Myers Squibb total assets from 2006 to 2018. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Bristol-Myers Squibb total assets for the quarter ending December 31, 2018 were $34.986B, a 4.28% increase year-over-year.
  • Bristol-Myers Squibb total assets for 2018 were $34.986B, a 4.28% increase from 2017.
  • Bristol-Myers Squibb total assets for 2017 were $33.551B, a 0.46% decline from 2016.
  • Bristol-Myers Squibb total assets for 2016 were $33.707B, a 6.17% increase from 2015.
Bristol-Myers Squibb Annual Total Assets
(Millions of US $)
2018 $34,986
2017 $33,551
2016 $33,707
2015 $31,748
2014 $33,749
2013 $38,592
2012 $35,897
2011 $32,970
2010 $31,076
2009 $31,008
2008 $29,486
2007 $25,926
2006 $25,575
2005 $28,138
Bristol-Myers Squibb Quarterly Total Assets
(Millions of US $)
Q4 2018 $34,986
Q3 2018 $33,734
Q2 2018 $32,641
Q1 2018 $33,083
Q4 2017 $33,551
Q3 2017 $33,977
Q2 2017 $33,409
Q1 2017 $32,937
Q4 2016 $33,707
Q3 2016 $33,727
Q2 2016 $32,831
Q1 2016 $31,892
Q4 2015 $31,748
Q3 2015 $31,779
Q2 2015 $31,954
Q1 2015 $33,579
Q4 2014 $33,749
Q3 2014 $33,450
Q2 2014 $33,503
Q1 2014 $33,424
Q4 2013 $38,592
Q3 2013 $36,804
Q2 2013 $36,252
Q1 2013 $35,958
Q4 2012 $35,897
Q3 2012 $36,044
Q2 2012 $31,667
Q1 2012 $32,408
Q4 2011 $32,970
Q3 2011 $32,014
Q2 2011 $31,833
Q1 2011 $30,851
Q4 2010 $31,076
Q3 2010 $31,885
Q2 2010 $31,051
Q1 2010 $30,753
Q4 2009 $31,008
Q3 2009 $30,951
Q2 2009 $29,809
Q1 2009 $29,693
Q4 2008 $29,486
Q3 2008 $28,476
Q2 2008 $28,064
Q1 2008 $26,325
Q4 2007 $25,926
Q3 2007 $26,098
Q2 2007 $27,175
Q1 2007 $26,091
Q4 2006 $25,575
Q3 2006 $27,215
Q2 2006 $27,402
Q1 2006 $27,461
Q4 2005 $28,138
Q3 2005 $25,609
Q2 2005 $25,233
Q1 2005 $28,407
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $74.378B $22.561B
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $368.953B 16.73
Pfizer (PFE) United States $234.424B 13.13
Merck (MRK) United States $197.334B 16.86
Novartis AG (NVS) Switzerland $176.507B 15.01
Eli Lilly (LLY) United States $119.326B 20.72
Novo Nordisk (NVO) Denmark $118.242B 19.13
AbbVie (ABBV) United States $114.422B 9.81
Sanofi (SNY) France $103.609B 12.79
GlaxoSmithKline (GSK) United Kingdom $98.852B 12.98
AstraZeneca (AZN) United Kingdom $98.276B 11.21